Therapeutic Advances in MG


Want a discount? Become a member by purchasing Corporate Membership, Enterprise Corporate Membership or Individual Membership!



Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc.

Release Date: November 1, 2023
Expiration Date: October 31, 2024

Speaker: James Howard, MD, FANN

Continuing Education: Nursing 1.0 contact hour | Pharmacy 1.0 contact hour |  Physician 1.0 AMA PRA Category 1 Credit(s)™

Recertification: 1 IgCN® / IgCP® Recertification Units

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals who care for patients in need of immunoglobulin therapy and specialty biologics.

Educational Objectives                                                   

Upon completion of this activity, participants should be able to:

  • Discuss the disease and treatment burdens of generalized myasthenia gravis
  • Explain the pathogenic mechanisms of disease in myasthenia gravis
  • Identify the role of FcRn inhibition in the treatment of myasthenia gravis
  • Describe the role of complement inhibition in myasthenia gravis